287 related articles for article (PubMed ID: 33574396)
1. Proton pump inhibitors associated acute kidney injury and chronic kidney disease: data mining of US FDA adverse event reporting system.
Wu B; Li D; Xu T; Luo M; He Z; Li Y
Sci Rep; 2021 Feb; 11(1):3690. PubMed ID: 33574396
[TBL] [Abstract][Full Text] [Related]
2. Acute kidney injury following the use of different proton pump inhibitor regimens: A real-world analysis of post-marketing surveillance data.
Chen G; Ning LJ; Qin Y; Zhao B; Mei D; Li XM
J Gastroenterol Hepatol; 2021 Jan; 36(1):156-162. PubMed ID: 32542684
[TBL] [Abstract][Full Text] [Related]
3. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
Welch HK; Kellum JA; Kane-Gill SL
Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
[TBL] [Abstract][Full Text] [Related]
4. Proton Pump Inhibitors and Risk of Acute and Chronic Kidney Disease: A Retrospective Cohort Study.
Hart E; Dunn TE; Feuerstein S; Jacobs DM
Pharmacotherapy; 2019 Apr; 39(4):443-453. PubMed ID: 30779194
[TBL] [Abstract][Full Text] [Related]
5. Adverse effects of proton pump inhibitors (PPIs) on the renal system using data mining algorithms (DMAs).
Jain D; Sharma G; Kumar A
Expert Opin Drug Saf; 2023; 22(8):741-752. PubMed ID: 36888736
[TBL] [Abstract][Full Text] [Related]
6. Assessment of acute kidney injury related to small-molecule protein kinase inhibitors using the FDA adverse event reporting system.
Fan Q; Ma J; Zhang B; Li Q; Liu F; Zhao B
Cancer Chemother Pharmacol; 2020 Nov; 86(5):655-662. PubMed ID: 33001273
[TBL] [Abstract][Full Text] [Related]
7. Surveillance of drugs that most frequently induce acute kidney injury: A pharmacovigilance approach.
Hosohata K; Inada A; Oyama S; Furushima D; Yamada H; Iwanaga K
J Clin Pharm Ther; 2019 Feb; 44(1):49-53. PubMed ID: 30014591
[TBL] [Abstract][Full Text] [Related]
8. Comparing Acute Kidney Injury Reports Among Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS).
Patek TM; Teng C; Kennedy KE; Alvarez CA; Frei CR
Drug Saf; 2020 Jan; 43(1):17-22. PubMed ID: 31691256
[TBL] [Abstract][Full Text] [Related]
9. Association between Concomitant Use of Acyclovir or Valacyclovir with NSAIDs and an Increased Risk of Acute Kidney Injury: Data Mining of FDA Adverse Event Reporting System.
Yue Z; Shi J; Li H; Li H
Biol Pharm Bull; 2018 Feb; 41(2):158-162. PubMed ID: 29187701
[TBL] [Abstract][Full Text] [Related]
10. Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury.
Xie Y; Bowe B; Li T; Xian H; Yan Y; Al-Aly Z
Kidney Int; 2017 Jun; 91(6):1482-1494. PubMed ID: 28237709
[TBL] [Abstract][Full Text] [Related]
11. Association between proton pump inhibitors and rhabdomyolysis risk: a post-marketing surveillance using FDA adverse event reporting system (FAERS) database.
Altebainawi AF; Alfaraj LA; Alharbi AA; Alkhuraisi FF; Alshammari TM
Ther Adv Drug Saf; 2023; 14():20420986231154075. PubMed ID: 36875514
[TBL] [Abstract][Full Text] [Related]
12. A pharmacovigilance study of association between proton pump inhibitor and dementia event based on FDA adverse event reporting system data.
Wu B; Hu Q; Tian F; Wu F; Li Y; Xu T
Sci Rep; 2021 May; 11(1):10709. PubMed ID: 34021217
[TBL] [Abstract][Full Text] [Related]
13. Risk factors of immune checkpoint inhibitor-associated acute kidney injury: evidence from clinical studies and FDA pharmacovigilance database.
Chen P; Zhu J; Xu Y; Huang Q; Su J; Gao Z; Feng M
BMC Nephrol; 2023 Apr; 24(1):107. PubMed ID: 37087434
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the Interaction between Clopidogrel, Aspirin, and Proton Pump Inhibitors Using the FDA Adverse Event Reporting System Database.
Suzuki Y; Suzuki H; Umetsu R; Uranishi H; Abe J; Nishibata Y; Sekiya Y; Miyamura N; Hara H; Tsuchiya T; Kinosada Y; Nakamura M
Biol Pharm Bull; 2015; 38(5):680-6. PubMed ID: 25947914
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin receptor-neprilysin inhibitor and sodium-dependent glucose cotransporter-2 inhibitor-associated renal injury: a pharmacovigilance study.
Chen C; Wu B; Zhang C; Xu T
Expert Opin Drug Saf; 2023 Mar; 22(3):259-266. PubMed ID: 36044355
[TBL] [Abstract][Full Text] [Related]
16. Remdesivir for COVID-19 and acute kidney injury: disproportionality analysis of data from the U.S. Food and Drug Administration Adverse Event Reporting System.
Li X; Zhou L; Gaggl M; Kinlaw AC; Gou Z; Xu Y; Wei J; Wang T
Int J Clin Pharm; 2023 Apr; 45(2):509-514. PubMed ID: 36964312
[TBL] [Abstract][Full Text] [Related]
17. Using proton pump inhibitors correlates with an increased risk of chronic kidney disease: a nationwide database-derived case-controlled study.
Hung SC; Liao KF; Hung HC; Lin CL; Lai SW; Lee PC; Hung SR
Fam Pract; 2018 Mar; 35(2):166-171. PubMed ID: 29045621
[TBL] [Abstract][Full Text] [Related]
18. Proton pump inhibitors and increased reporting odds of renal neoplasms: FAERS-based adverse event data mining and analysis.
Song W; Shi L; Wang Y; Zhang Z
Expert Opin Drug Saf; 2022 May; 21(5):707-713. PubMed ID: 34915780
[TBL] [Abstract][Full Text] [Related]
19. Proton Pump Inhibitors and the Risk for Fracture at Specific Sites: Data Mining of the FDA Adverse Event Reporting System.
Wang L; Li M; Cao Y; Han Z; Wang X; Atkinson EJ; Liu H; Amin S
Sci Rep; 2017 Jul; 7(1):5527. PubMed ID: 28717153
[TBL] [Abstract][Full Text] [Related]
20. Acute renal failure and cardiac arrhythmias associated with remdesivir use in patients with COVID-19 infections: Analysis using the US FDA adverse event reporting system.
Orogun L; Chyou TY; Nishtala PS
Int J Risk Saf Med; 2023; 34(2):87-99. PubMed ID: 37154187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
